The Feasibility of Physical Activity in Advanced Cancer Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT00438620
First received: February 20, 2007
Last updated: January 18, 2012
Last verified: January 2012
  Purpose

Physical activity has been shown to have a positive effect on several quality of life outcomes in cancer patients, but few existing studies have focused on the end stages of cancer. The aim of this pilot study is to test the feasibility of a physical activity intervention in advanced cancer patients, from which data can be used to design a randomized controlled trial if results are encouraging.


Condition Intervention
Advanced Cancer
Behavioral: Home-based physical activity program

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Pilot Study to Explore the Role of Physical Activity as a Quality of Life Intervention in Advanced Cancer Patients

Resource links provided by NLM:


Further study details as provided by AHS Cancer Control Alberta:

Enrollment: 30
Study Start Date: October 2006
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Behavioral: Home-based physical activity program
    the role of physical activity as a Quality of Life intervention
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Advanced Cancer Patients

Criteria

Inclusion Criteria:

  • 18 years of age or older
  • able to understand, provide written consent in and speak English
  • cognitive ability to participate
  • clinician-estimated life expectancy between 3 and 12 months
  • approval of treating physician

Exclusion Criteria:

  • any absolute contraindications to physical activity
  • palliative performance scale level of 30% of less
  • any patient within the last days to hour of life
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00438620

Locations
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Investigators
Study Chair: Kerry Courneya, PhD AHS Cancer Control Alberta
  More Information

No publications provided

Responsible Party: AHS Cancer Control Alberta
ClinicalTrials.gov Identifier: NCT00438620     History of Changes
Other Study ID Numbers: PS-08-0054
Study First Received: February 20, 2007
Last Updated: January 18, 2012
Health Authority: Canada: Health Canada

Additional relevant MeSH terms:
Neoplasms

ClinicalTrials.gov processed this record on April 16, 2014